Safety and tolerability of recombinant modified vaccinia virus Ankara expressing an HIV-1 gag/multiepitope immunogen (MVA.HIVA) in HIV-1-infected persons receiving combination antiretroviral therapy.
The safety of attenuated poxviruses in HIV-1-infected individuals is an important consideration in their application as vaccine vectors, first, because new HIV-1 infections may occur in vaccine trials involving persons at high risk of infection and secondly, therapeutic vaccinations are a potential...
| Main Authors: | , , , , , , , |
|---|---|
| Format: | Journal article |
| Language: | English |
| Published: |
2007
|
| _version_ | 1826283369836576768 |
|---|---|
| author | Dorrell, L Williams, P Suttill, A Brown, D Roberts, J Conlon, C Hanke, T McMichael, A |
| author_facet | Dorrell, L Williams, P Suttill, A Brown, D Roberts, J Conlon, C Hanke, T McMichael, A |
| author_sort | Dorrell, L |
| collection | OXFORD |
| description | The safety of attenuated poxviruses in HIV-1-infected individuals is an important consideration in their application as vaccine vectors, first, because new HIV-1 infections may occur in vaccine trials involving persons at high risk of infection and secondly, therapeutic vaccinations are a potential means to enhance virus-specific immune responses once infection has occurred. We administered a candidate modified vaccinia virus Ankara-vectored HIV-1 vaccine, MVA.HIVA, by intradermal injection to 16 chronically infected adults during highly active antiretroviral therapy. Vaccinations were well tolerated and there were no serious adverse events. No breakthrough viraemia occurred after immunisations or throughout follow-up. These data confirm the safety of MVA.HIVA in HIV-1-infected individuals and provide support for further evaluation of MVA-vectored vaccines in prophylactic and therapeutic immunisation strategies. |
| first_indexed | 2024-03-07T00:57:53Z |
| format | Journal article |
| id | oxford-uuid:88b76366-edba-48c3-950e-026161e93db3 |
| institution | University of Oxford |
| language | English |
| last_indexed | 2024-03-07T00:57:53Z |
| publishDate | 2007 |
| record_format | dspace |
| spelling | oxford-uuid:88b76366-edba-48c3-950e-026161e93db32022-03-26T22:19:15ZSafety and tolerability of recombinant modified vaccinia virus Ankara expressing an HIV-1 gag/multiepitope immunogen (MVA.HIVA) in HIV-1-infected persons receiving combination antiretroviral therapy.Journal articlehttp://purl.org/coar/resource_type/c_dcae04bcuuid:88b76366-edba-48c3-950e-026161e93db3EnglishSymplectic Elements at Oxford2007Dorrell, LWilliams, PSuttill, ABrown, DRoberts, JConlon, CHanke, TMcMichael, AThe safety of attenuated poxviruses in HIV-1-infected individuals is an important consideration in their application as vaccine vectors, first, because new HIV-1 infections may occur in vaccine trials involving persons at high risk of infection and secondly, therapeutic vaccinations are a potential means to enhance virus-specific immune responses once infection has occurred. We administered a candidate modified vaccinia virus Ankara-vectored HIV-1 vaccine, MVA.HIVA, by intradermal injection to 16 chronically infected adults during highly active antiretroviral therapy. Vaccinations were well tolerated and there were no serious adverse events. No breakthrough viraemia occurred after immunisations or throughout follow-up. These data confirm the safety of MVA.HIVA in HIV-1-infected individuals and provide support for further evaluation of MVA-vectored vaccines in prophylactic and therapeutic immunisation strategies. |
| spellingShingle | Dorrell, L Williams, P Suttill, A Brown, D Roberts, J Conlon, C Hanke, T McMichael, A Safety and tolerability of recombinant modified vaccinia virus Ankara expressing an HIV-1 gag/multiepitope immunogen (MVA.HIVA) in HIV-1-infected persons receiving combination antiretroviral therapy. |
| title | Safety and tolerability of recombinant modified vaccinia virus Ankara expressing an HIV-1 gag/multiepitope immunogen (MVA.HIVA) in HIV-1-infected persons receiving combination antiretroviral therapy. |
| title_full | Safety and tolerability of recombinant modified vaccinia virus Ankara expressing an HIV-1 gag/multiepitope immunogen (MVA.HIVA) in HIV-1-infected persons receiving combination antiretroviral therapy. |
| title_fullStr | Safety and tolerability of recombinant modified vaccinia virus Ankara expressing an HIV-1 gag/multiepitope immunogen (MVA.HIVA) in HIV-1-infected persons receiving combination antiretroviral therapy. |
| title_full_unstemmed | Safety and tolerability of recombinant modified vaccinia virus Ankara expressing an HIV-1 gag/multiepitope immunogen (MVA.HIVA) in HIV-1-infected persons receiving combination antiretroviral therapy. |
| title_short | Safety and tolerability of recombinant modified vaccinia virus Ankara expressing an HIV-1 gag/multiepitope immunogen (MVA.HIVA) in HIV-1-infected persons receiving combination antiretroviral therapy. |
| title_sort | safety and tolerability of recombinant modified vaccinia virus ankara expressing an hiv 1 gag multiepitope immunogen mva hiva in hiv 1 infected persons receiving combination antiretroviral therapy |
| work_keys_str_mv | AT dorrelll safetyandtolerabilityofrecombinantmodifiedvacciniavirusankaraexpressinganhiv1gagmultiepitopeimmunogenmvahivainhiv1infectedpersonsreceivingcombinationantiretroviraltherapy AT williamsp safetyandtolerabilityofrecombinantmodifiedvacciniavirusankaraexpressinganhiv1gagmultiepitopeimmunogenmvahivainhiv1infectedpersonsreceivingcombinationantiretroviraltherapy AT suttilla safetyandtolerabilityofrecombinantmodifiedvacciniavirusankaraexpressinganhiv1gagmultiepitopeimmunogenmvahivainhiv1infectedpersonsreceivingcombinationantiretroviraltherapy AT brownd safetyandtolerabilityofrecombinantmodifiedvacciniavirusankaraexpressinganhiv1gagmultiepitopeimmunogenmvahivainhiv1infectedpersonsreceivingcombinationantiretroviraltherapy AT robertsj safetyandtolerabilityofrecombinantmodifiedvacciniavirusankaraexpressinganhiv1gagmultiepitopeimmunogenmvahivainhiv1infectedpersonsreceivingcombinationantiretroviraltherapy AT conlonc safetyandtolerabilityofrecombinantmodifiedvacciniavirusankaraexpressinganhiv1gagmultiepitopeimmunogenmvahivainhiv1infectedpersonsreceivingcombinationantiretroviraltherapy AT hanket safetyandtolerabilityofrecombinantmodifiedvacciniavirusankaraexpressinganhiv1gagmultiepitopeimmunogenmvahivainhiv1infectedpersonsreceivingcombinationantiretroviraltherapy AT mcmichaela safetyandtolerabilityofrecombinantmodifiedvacciniavirusankaraexpressinganhiv1gagmultiepitopeimmunogenmvahivainhiv1infectedpersonsreceivingcombinationantiretroviraltherapy |